Avaliação De Mirnas E Mediadores Solúveis Como Biomarcadores Diagnósticos, Prognósticos E Preditivos No Câncer De Mama
Year: 2026
Type: article
Abstract: Introduction: Breast cancer (BC) is one of the leading causes of female mortality worldwide. It comprises a group of genetically and clinically heterogeneous diseases, primarily classified based on the expression of hormone receptors and HER2, which guide therapeutic decisions. However, even within the same molecular subtype, patients may exhibit distinct outcomes influenced by both individual genetic characteristics and the tumor microenvironment. In this microenvironment, soluble mediators and various molecules interact, playing key roles in tumor progression and potentially serving as biomarkers due to their presence in the bloodstream. Thus, the minimally invasive liquid biopsy enables access to biological information representative of the tumor. This approach allows for early diagnosis, prognostic stratification, and treatment personalization. Therefore, investigating less invasive methods integrated with clinical and molecular data is essential to improve BC management. Our hypothesis is that combined analyses of different microRNAs and soluble markers may contribute to predicting BC outcomes.Objective: To evaluate the applicability of quantifying miRNAs and soluble mediators previously described in the literature as diagnostic, prognostic, and predictive tools for BC.Methodology: The study was approved by the Ethics Committee (CAAE: 77040124.0.0000.5091). BC patients will be recruited upon informed consent. Peripheral blood will be collected in heparin tubes to obtain plasma and PBMCs using Ficoll® Paque. Samples will be aliquoted and stored at –80 °C. Clinical data will be extracted from the MV PEP 2000i system and recorded in REDCap. Total plasma RNA will be isolated using TRIzol®, and PBMC miRNA will be extracted with the EZ2 RNA/miRNA Tissue/Cells kit (Qiagen). The expression of 12 miRNAs will be analyzed by RT-qPCR, and 48 soluble mediators will be quantified using Luminex technology. Statistical analyses will be performed in GraphPad Prism.Preliminary results: A total of 79 control participants and 48 BC patients (mean age 54 years) have been recruited, with Invasive Ductal Carcinoma and Luminal A subtype being predominant. miRNA extraction and RT-qPCR procedures have been standardized. The next steps include expanding sample collection and analyzing miRNAs and inflammatory mediators.Conclusion: The integration of clinical, molecular, and inflammatory data may identify potential biomarkers, reinforcing the use of minimally invasive approaches in BC management.
Source: Mário Penna Journal
DOI: 10.61229/mpj.v3i1.74
Institution: Fiocruz Minas
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: breast cancer, microRNA, soluble mediators, liquid biopsy, circulating biomarkers, prognostic factors, diagnostic biomarkers, predictive biomarkers, peripheral blood mononuclear cells, plasma RNA, inflammatory mediators, tumor microenvironment, breast cancer subtypes, invasive ductal carcinoma, luminal A, personalized treatment, tumor progression, early diagnosis, prognostic stratification
Open Access status: hybrid
OpenAlex ID: W7223450856
